In the BCIRG006 and HERA subgroup analyses adjuvant trastuzumab did not result in different rates of risk reduction among HER2-positive breast cancers in function of nodal status or tumour size [35,39,40]. This evidence concerns the gene ERAL1 and breast carcinoma.